Overview

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Status:
Completed

Trial end date:
2018-10-01

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Carmustine
Cyclophosphamide
Cyclosporine
Cyclosporins
Cytarabine
Etoposide
Etoposide phosphate
Fludarabine
Fludarabine phosphate
Mechlorethamine
Melphalan
Mycophenolate mofetil
Mycophenolic Acid
Nitrogen Mustard Compounds
Podophyllotoxin